Latest MYDICARÂ® Stories
LA JOLLA, Calif., March 23 /PRNewswire/ -- Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICARÃ®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon. When issued, the patent will cover the use of...
- To talk saucily.
- Insolent, opprobrious language; impertinent abuse.